Valneva is a specialty vaccine company focused on prevention of infectious diseases with significant unmet need. Its commercial portfolio has included vaccines against Japanese encephalitis and cholera, and it has advanced programs such as a chikungunya vaccine and candidates for other infectious threats including Lyme disease. Research, manufacturing, and commercial activities serve travelers, military, and public-health markets that require specialized immunization products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 48.3 | — | -11.6 | — |
| Q3 2025 | 29.4 | — | -44.4 | — |
| Q4 2025 | 47.7 | — | -50 | — |
| Q1 2026 | 30.9 | — | -32.1 | — |
| Q2 2026 | 34.9 | -27.7% | -31.2 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: ProKidney Corp. (PROK), Yuanbao Inc. (YB), SBC Medical Group Holdings Incorporated (SBC), Array Technologies, Inc. (ARRY), Forward Industries, Inc. (FWDI), Kelly Services, Inc. (KELYA)